Dexcom has announced that the U.S. Food and Drug Administration has cleared its G7 15 Day Continuous Glucose Monitoring ...

The Dexcom G7 15 Day CGM system is a wearable sensor that continuously measures glucose levels and transmits readings every 5 minutes with no fingersticks or scanning required.

Once-weekly basal insulin combined with an intermittently scanned continuous glucose monitor reduced HbA1c and improved time ...

DexCom, Inc. DXCM recently announced the FDA clearance for its 15-day wear G7 Continuous Glucose Monitoring (CGM) system, the ...

Dexcom has been cash flow positive for since 2014 and more recently moved into positive earnings territory. While revenue has grown very quickly, research and development expenses and selling, general ...

The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users.

A group of experts discusses the use of continuous glucose monitoring (CGM) technology in diabetes and its transformative potential in managing the disease.

San Diego-based Dexcom submitted its 15-day G7 CGM to the FDA in October 2024. The company says its 15-day G7 also meets ...

The longer wear time should improve Dexcom’s margins and help it compete with Abbott, RBC Capital Markets analyst Shagun ...

The Food and Drug Administration has cleared diabetes-management firm DexCom's new continuous glucose monitoring (CGM) system ...

CGM approved by FDA for adults with diabetes; U.S. launch set for late 2025 with extended wear and advanced tracking features ...